2型糖尿病(T2DM)肥胖患者应用恩格列净联合胰岛素强化治疗的临床效果  

Clinical Effect of Enpagliflozin Combined with Insulin Intensive Treatment in Obese Patients with Type 2 Diabetes(T2DM)

作　　者：张陈芬 ZHANG Chenfen(Xiamen Haicang Hospital,Xiamen,Fujian Province,361000 China)

机构地区：[1]厦门市海沧医院,福建厦门361000

出　　处：《糖尿病新世界》2021年第15期97-100,共4页Diabetes New World Magazine

摘　　要：目的研究2型糖尿病肥胖患者在临床治疗中应用恩格列净联合胰岛素强化治疗的临床效果。方法选择该院2020年1月—2021年5月期间收治的2型糖尿病肥胖患者(n=74)为研究对象,根据随机抽签方式分为参照组(n=37)与观察组(n=37);参照组患者施以强化胰岛素治疗方式,观察组患者施以恩格列净联合胰岛素强化治疗,对两组患者临床治疗效果予以分析和比较。结果观察组患者每日胰岛素总量(31.12±4.83)U/d、体质指数(24.15±4.79)kg/m2、空腹血糖(6.73±1.12)mmol/L、餐后2 h血糖(8.51±2.08)mmol/L、糖化血红蛋白(7.05±1.36)%、总胆固醇(4.84±0.42)mmol/L、三酰甘油(1.42±0.24)mmol/L、低密度脂蛋白(3.14±0.39)mmol/L,其数据与对照组进行对比,差异有统计学意义(t=24.583,P<0.001;t=3.290,P=0.001;t=2.243,P=0.028;t=5.258,P<0.001;t=4.677,P<0.001;t=2.117,P=0.037;t=3.390,P=0.001;t=3.183,P=0.002);观察组患者不良反应发生率为5.4%,显著低于对照组,差异有统计学意义(χ^(2)=4.162,P=0.041)。结论联合恩格列净与强化胰岛素治疗方式可以改善患者血糖和血脂水平,有利于患者BMI指数的调整,对患者的临床治疗具有重要价值。Objective To study the clinical effect of enpagliflozin combined with intensive insulin therapy in obese patients with type 2 diabetes.Methods The obese patients with type 2 diabetes(n=74)admitted to the hospital from January 2020 to May 2021 were selected as the research subjects,and divided into reference group(n=37)and observation group(n=37);the treatment mode of the reference group was intensive insulin therapy,and the treatment mode of the observation group was empagliflozin combined with intensive insulin therapy.The clinical treatment effects of the two groups of patients were analyzed and compared.Results The total daily insulin of the observation group was(31.12±4.83)U/d,body mass index(24.15±4.79)kg/m2,fasting blood glucose(6.73±1.12)mmol/L,and postprandial 2 h blood glucose(8.51±2.08)mmol/L,glycosylated hemoglobin(7.05±1.36)%,total cholesterol(4.84±0.42)mmol/L,triglycerides(1.42±0.24)mmol/L,low-density lipoprotein(3.14±0.39)mmol/L,which had a significant advantage in comparing the data with the control group,the difference was statistically significant(t=24.583,P<0.001;t=3.290,P=0.001;t=2.243,P=0.028;t=5.258,P<0.001;t=4.677,P<0.001;t=2.117,P=0.037;t=3.390,P=0.001;t=3.183,P=0.002);the incidence of adverse reactions in the observation group was 5.4%,the difference was statistically significant(χ^(2)=4.162,P=0.041).Conclusion The combination of empagliflozin and intensive insulin therapy can improve the blood glucose and blood lipid levels of patients,which is beneficial to the adjustment of the patient’s BMI index,and is of great value to the clinical treatment of patients.

关 键 词：2型糖尿病 肥胖 恩格列净 强化胰岛素 血糖水平 

分 类 号：R59[医药卫生—内科学]